[HTML][HTML] Evaluating WHO, CCI, and CFS Performance in Predicting Non-small cell Lung Cancer Survival in Finland: Insights Beyond CONCORD-3
V Paappanen - 2024 - scholarworks.utrgv.edu
Background: Set against the backdrop of the 2018 CONCORD-3 study, our research focuses
on Finland's lung cancer survival rates. Despite similar tax-funded and public healthcare …
on Finland's lung cancer survival rates. Despite similar tax-funded and public healthcare …
What is a clinically meaningful change on the functional assessment of Cancer therapy–lung (FACT-L) questionnaire?: results from eastern cooperative oncology …
D Cella, DT Eton, DL Fairclough, P Bonomi… - Journal of clinical …, 2002 - Elsevier
To assess the impact of disease and treatment on patients with advanced non-small cell
lung cancer (NSCLC), we set out to determine a clinically meaningful change (CMC) on the …
lung cancer (NSCLC), we set out to determine a clinically meaningful change (CMC) on the …
Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy
We appreciate our colleagues' interest in our recent article entitled 'Predictive ability of a
drug-based score in patients with advanced non-small-cell lung cancer receiving first-line …
drug-based score in patients with advanced non-small-cell lung cancer receiving first-line …
Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status
K Kelly - Seminars in oncology, 2004 - Elsevier
Performance status (PS), a subjective measure of the functional status of a patient with
cancer and his or her ability to perform normal activities, is influenced both by tumor-related …
cancer and his or her ability to perform normal activities, is influenced both by tumor-related …
Augmenting real-world data through modeling key clinical trial eligibility criteria: an example of patients with non–small-cell lung cancer treated with pembrolizumab
T Jemielita, X Li, T Burke, KL Liaw, W Zhou… - JCO Clinical Cancer …, 2021 - ascopubs.org
PURPOSE To compare and characterize baseline characteristics and overall survival (OS)
differences by key oncology eligibility criteria for real-world patients from the Flatiron Health …
differences by key oncology eligibility criteria for real-world patients from the Flatiron Health …
Quality-of-life (QoL) measures in advanced non-small cell lung cancer (NSCLC) patients and their association with treatment choices across 5 European countries …
F Pimental, A Szczepura, M Thomas… - Journal of Clinical …, 2005 - ascopubs.org
8081 Background: ACTION (Assessment of Cost and ouTcomes of chemotherapy In an
Observational setting in patients with advanced NSCLC) is an on-going, pan-European …
Observational setting in patients with advanced NSCLC) is an on-going, pan-European …
EP06. 01-01 Concordance Between Generative AI GPT-4 and NCCN Guidelines: Biomarker-Driven Treatment Strategies in NSCLC
HS Kim, J Lee, YK Chae - Journal of Thoracic Oncology, 2023 - Elsevier
Methods We compared NSCLC biomarker-based treatment recommendations between
Generative Pretrained Transformer 4 (GPT-4), the most advanced AI system developed by …
Generative Pretrained Transformer 4 (GPT-4), the most advanced AI system developed by …
Prognostic value of Lung Cancer Subscale in older patients with advanced non-small cell lung cancer: An integrated analysis of JCOG0207 and JCOG0803 …
T Mizutani, M Ando, J Mizusawa, K Nakamura… - Journal of geriatric …, 2018 - Elsevier
Abstract Objective The Lung Cancer Subscale (LCS) of the Functional Assessment of
Cancer Therapy-Lung (FACT-L) questionnaire is commonly used for evaluating lung cancer …
Cancer Therapy-Lung (FACT-L) questionnaire is commonly used for evaluating lung cancer …
[HTML][HTML] The influence of comorbidity and the simplified comorbidity score on overall survival in non–small cell lung Cancer—a prospective cohort study
Introduction We addressed the uncertainty of comorbidity as a prognosticator by evaluating
comorbidity and the Simplified Comorbidity Score (SCS) as predictors of overall survival in …
comorbidity and the Simplified Comorbidity Score (SCS) as predictors of overall survival in …
Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma Patients (CRISP): A prospective German registry in stage IV …
F Griesinger, W Eberhardt, N Marschner… - Annals of …, 2017 - annalsofoncology.org
Background: Treatment in NSCL is quickly evolving and new agents make it to the routine
practice at a rapid pace. Whether outcome and PRO data generated in clinical trials with …
practice at a rapid pace. Whether outcome and PRO data generated in clinical trials with …